On April 29, 2026, Avory & Corporate, LLC disclosed in a U.S. Securities and Alternate Fee (SEC) submitting that it bought 156,571 stocks of Omnicell (OMCL 2.94%), an estimated $6.55 million transaction in response to the quarterly moderate value.
What took place
In step with its SEC submitting dated April 29, 2026, Avory & Corporate, LLC lowered its place in Omnicell by means of 156,571 stocks, an estimated $6.55 million transaction in response to the common first-quarter 2026 last value. The quarter-end worth of the Omnicell stake declined by means of $8.01 million, a determine that displays each the relief in stocks and Omnicell’s value motion over the duration. The fund’s post-sale conserving in Omnicell was once 77,137 stocks, valued at $2.57 million.
What else to grasp
Following the sale, Omnicell represents 3.33% of Avory & Corporate, LLC’s reportable property underneath control.
Most sensible 5 holdings after the submitting:
- NYSEMKT: VOO: $17.22 million (22.3% of AUM)
- NASDAQ: ZM: $8.59 million (11.1% of AUM)
- NYSE: XYZ: $7.41 million (9.6% of AUM)
- BATS: AVRY: $7.29 million (9.4% of AUM)
- NASDAQ: Z: $4.27 million (5.5% of AUM)
As of April 28, 2026, Omnicell stocks had been priced at $45.51, up 47.6% during the last 12 months, outperforming the S&P 500 by means of 18.45 proportion issues.
Corporate assessment
| Metric | Price |
|---|---|
| Earnings (TTM) | $1.19 billion |
| Web source of revenue (TTM) | $2.052 million |
| Marketplace capitalization | $2.07 billion |
| Worth (as of marketplace shut April 28, 2026) | $45.51 |
Corporate snapshot
- Omnicell supplies medicine control answers, together with computerized shelling out methods, pharmacy automation, and adherence packaging for healthcare methods and pharmacies
- The corporate generates earnings basically in the course of the sale and servicing of automation apparatus, device answers, and comparable consumables that optimize medicine distribution and stock control
- Its number one shoppers are hospitals, well being methods, institutional pharmacies, and retail pharmacies in the hunt for to support medicine protection, potency, and regulatory compliance
Omnicell operates at scale within the healthcare generation sector, serving over 3,600 staff and producing greater than $1.20 billion in annual earnings. The corporate’s technique facilities on handing over built-in automation and device answers that streamline medicine control throughout care settings. Omnicell’s aggressive edge lies in its complete product suite and concentrate on workflow automation, which allows healthcare suppliers to strengthen affected person protection and operational potency.
What this transaction way for buyers
Avory & Corporate, a Florida-based funding guide, just lately disclosed the sale of roughly $6.6 million value of Omnicell inventory throughout the primary quarter (the 3 months finishing on March 31, 2026). Listed below are some key takeaways for buyers.
First, Omnicell inventory has struggled over the previous couple of years. Since 2021, stocks have declined by means of 68%, with a compound annual enlargement price (CAGR) of -20.8%. That’s neatly beneath the go back produced by means of the S&P 500 over the similar duration — a 83% overall go back and a CAGR of 12.8%.
At any price, Omnicell just lately reported robust first-quarter income, led by means of $310 million in earnings (up 15% year-over-year). Web source of revenue was once $11 million, up from a web lack of -$7 million twelve months in the past.
In abstract, Omnicell inventory is playing a spice up from a favorable income record. On the other hand, the inventory’s long-term observe report of underperformance can give some buyers pause.
